School of Medicine
Showing 81-100 of 4,450 Results
-
Israt Alam
Senior Research Scientist-Basic Life, Rad/Molecular Imaging Program at Stanford
BioResearch Focus and interests: Molecular Imaging, Clinical Translation, Graft versus Host Disease, Spatial Biology, Immune-Theragnostics
Dr. Israt Alam is a Senior Scientist in the Radiology Department at Stanford University. She trained in Prof. Sanjiv Sam Gambhir's lab and transitioned to Dr. Michelle James' lab in 2021. Her research focuses on studying lymphocyte activation with the motivation of developing non-invasive imaging tools, to monitor immune dynamics in response to cancer immunotherapy and in immunopathology. Her work has supported the clinical translation of several nuclear imaging agents (small molecules and a biologic) for early detection of cancer and prediction of treatment response, that are being evaluated in oncology trials around the world. She is currently leading the IND-enabling studies for a first in class PET tracer for T cell activation and has also supported several biomarker detection platforms for early disease detection. She was elected as Co-Chair of the "Imaging in cell and immune therapies" (ICIT) interest group for the World Molecular Imaging Society (WMIS).
Key funding: (grant conceptualization/scientific lead): NIH/NCI R01, Pfizer Inc., SNMMI Education and Research Foundation
Appointments:
-Senior Research Scientist, James Lab, Department of Radiology, Stanford
-Life Sciences Research Associate, Gambhir Lab, Department of Radiology, Stanford
-Post-Doctoral Scholar, Gambhir Lab, Department of Radiology, Stanford
-Churchill Travel Fellow in the Plateforme d'imagerie dynamique lab of Prof. Spencer Shorte, Pasteur Institute, Paris
-Science Education Consultant: United Nations Educational, Science and Cultural Organization (UNESCO), Paris
-Science Education Intern: United Nations Educational, Science and Cultural Organization (UNESCO), Paris -
Arash Alavi
Software Engineering Director, Genetics
Current Role at StanfordSoftware Engineering Director
-
Alawab Aldulimy
Clinical Rsch Coord Assoc, CV Med - Clinical Trials
Current Role at StanfordClinical Researcher
Clinical Research Coordinator -
William Alegria
Lecturer, Medicine - Med/Infectious Diseases
BioDr. Alegria is a board-certified Infectious Diseases Pharmacotherapy specialist and antimicrobial stewardship consultant with the Stanford Antimicrobial Safety and Sustainability Program. He primarily practices in the inpatient setting and is dedicated to developing targeted stewardship interventions in immunocompromised patient populations. His clinical interests include management of infections in immunocompromised hosts, antifungal pharmacotherapy, and difficult-to-treat infections.
Publications (selected)
Navigating recurrent Clostridioides difficile infection without Bezlotoxumab: potential challenges ahead. Arya R, Zimmet AN, Holubar M, Alegria W. Antimicrob Steward Healthc Epidemiol. 2025
How to leverage medication use evaluations for antimicrobial stewardship goals: a primer for physicians. Prasad R, Arya R, Meng L, Holubar M, Alegria W, Zimmet AN.
Antimicrob Steward Healthc Epidemiol. 2025
Beyond the basics: rethinking antimicrobial stewardship by targeting cytomegalovirus immune globulin for immunocompromised patients. Prasad R, Lu B, Veloria D, Mui E, Nelson J, Dhillon G, Deresinski S, Holubar M, Alegria W. Antimicrob Steward Healthc Epidemiol. 2025
No "One-Size-Fits All": chronic "Carryover" diagnoses dilute antibiotic prescribing rates for sinusitis among adults in primary and urgent care settings. Smith M, Hawkins M, Laikijrung C, Mui E, Alegria W, Leung T, Zimmet A, Ha D, Holubar M. Infect Control Hosp Epidemiol. 2024
Combination Antifungal Therapy for Invasive Mucormycosis in Immunocompromised Hosts: A Single-Center Experience. Lu B, Ha D, Shen S, Ferguson Toll J, Kim A, Kim S, Mui E, Deresinski S, Holubar M, Alegria W. Open Forum Infect Dis. 2024
"Electronic Phenotyping" Antimicrobials to Facilitate Outpatient Stewardship for Asymptomatic Bacteriuria and Urinary Tract Infection in Renal Transplant. Zimmet AN, Ha D, Mui E, Smith M, Hawkins M, Alegria W, Holubar M. Open Forum Infect Dis. 2024
Risk factors and outcomes associated with persistent vancomycin resistant Enterococcal Bacteremia. Fox E, Ha D, Bounthavong M, Meng L, Mui E, Holubar M, Deresinski S, Alegria W. BMC Infect Dis. 2022
Shorter durations of antibiotic therapy in organ transplant. Alegria W, Medvedeva N, Holubar M. Curr Opin Organ Transplant. 2022
Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent. On S, Rath CG, Lan M, Wu B, Lau KM, Cheung E, Alegria W, Young R, Tan M, Kim C, Phun J, Patel N, Mannis G, Logan AC, Kennedy V, Goodman A, Taplitz RA, Young PA, Wen R, Saunders IM. Br J Haematol. 2022
Early Antibiotic Discontinuation or De-escalation in High-Risk Patients With AML With Febrile Neutropenia and Prolonged Neutropenia. Alegria W, Marini BL, Gregg KS, Bixby DL, Perissinotti A, Nagel J. J Natl Compr Canc Netw. 2022
Effect of rapid methicillin-resistant Staphylococcus aureus nasal polymerase chain reaction screening on vancomycin use in the intensive care unit. Diep C, Meng L, Pourali S, Hitchcock MM, Alegria W, Swayngim R, Ran R, Banaei N, Deresinski S, Holubar M. Am J Health Syst Pharm. 2021 Dec
The Current State of Antifungal Stewardship in Immunocompromised Populations. Alegria W, Patel PK. J Fungi (Basel). 2021
Bacteremia due to Methicillin-Resistant Staphylococcus aureus: An Update on New Therapeutic Approaches. Holubar M, Meng L, Alegria W, Deresinski S. Infect Dis Clin North Am. 2020
Impact of Rapid Antimicrobial Susceptibility Testing in Gram-Negative Rod Bacteremia: a Quasi-experimental Study. Hogan CA, Ebunji B, Watz N, Kapphahn K, Rigdon J, Mui E, Meng L, Alegria W, Holubar M, Deresinski S, Banaei N. J Clin Microbiol. 2020
Antimicrobial Stewardship in Cancer Patients: The Time is Now. Aitken SL, Nagel JL, Abbo L, Alegria W, Barreto JN, Dadwal S, Freifeld AG, Jain R, Pergam SA, Tverdek FP, Seo SK; Antimicrobial Stewardship in Cancer Consortium ASCC. J Natl Compr Canc Netw. 2019 -
Dr. Lydia Aletraris
Social Science Research Scholar, Health Policy
BioDr. Lydia Aletraris brings both a national and global perspective to her research, specializing in substance use and human trafficking. With extensive experience managing projects funded by agencies such as the National Institutes of Health, the Substance Abuse and Mental Health Services Administration, the U.S. Department of Justice, and the U.S. Department of State, she has served as Principal Investigator or Co-Principal Investigator on national research examining the implementation of evidence-based practices in substance use treatment and the effects of U.S. cannabis policy, as well as on international research focused on human trafficking.
Dr. Aletraris previously coordinated the Prevalence Reduction Innovation Forum (PRIF), a global initiative that developed key trafficking indicators and brought together scholars from around the world to test methodologies for measuring human trafficking prevalence, with studies conducted in Brazil, Costa Rica, Morocco, Pakistan, Tanzania, and Tunisia.
With a commitment to health and human rights, her research addresses urgent public health challenges through ethical, evidence-based practices and policies that support resilience and recovery across diverse, at-risk populations. Dr. Aletraris holds a PhD in Sociology from the University of Georgia.
